Investorideas.com newswire, defense and security sector

Tuesday, December 2, 2014

Ongoing Cyber Threats and Recent Sony Hacking Draw Attention to Cybersecurity Stocks

Ongoing Cyber Threats and Recent Sony Hacking Draw Attention to Cybersecurity Stocks

New York NY- Point Roberts WA–December 2, 2014 – Investorideas.com (www.investorideas.com), a global news source covering leading sectors including cybersecurity releases the updated cybersecurity stock directory for December, following the recent high – profile Sony hacking.

The recent hacking at Sony Pictures  by a group working under #GOP has resulted in the illegal release and distribution of  "Still Alice,'' ''Annie," ''Mr. Turner," and ''To Write Love on Her Arms".

With new cyber threats emerging daily, the sector has gained attention from investors and institutions.

It has also resulted in the recent launch of PureFunds ISE Cyber Security™ ETF (HACK).

Investorideas.com recently interviewed Christian Magoon, consultant to ISE ETF Ventures and Founder and CEO of YieldShares, to gain insight into the creation of the ETF and its future.


CyberSecurity Stocks Directory Preview
Absolute Software Corporation (TSX: ABT.TO) is the industry standard in persistent endpoint security and management for computers, laptops, tablets and smartphones. The Company, a leader in device security and management tracking for 20 years, has over 30,000 commercial customers worldwide. Absolute's solutions - Computrace®, Absolute Manage®, Absolute Service, Absolute Secure Drive, and Absolute LoJack® - provide organizations with actionable intelligence to prove compliance, securely manage BYOD, and deliver comprehensive visibility and control over all of their devices and data. Absolute is positioned on two Gartner, Inc. Magic Quadrants - the Magic Quadrant for Client Management Tools and the Magic Quadrant for Mobile Device Management Software. Absolute is one of only four vendors to be recognized on both Magic Quadrants based on providing customers with the ability to secure and manage many different types of devices using a single solution. Absolute persistence technology is embedded in the firmware of computers, netbooks, tablets and smartphones by global leaders, including Acer, ASUS, Dell, Fujitsu, HP, Lenovo, Motion, Panasonic, Samsung, and Toshiba, and the Company has reselling partnerships with these OEMs and others, including Apple.
AT&T Inc. (NYSE: T) AT&T Government Services (AGS), a business unit of AT&T Corp., delivers IT solutions spanning cyber security, networking, wireless, mission support and applications. Thousands of experienced AGS personnel, along with certified professionals throughout the AT&T family of companies, focus exclusively on supporting the federal government.
AVG Technologies N.V. (NYSE:AVG) is the online security company providing leading software and services to secure devices, data and people.  AVG has over 182 million active users, as of June 30, 2014, using AVG's products and services including Internet security, performance optimization, and personal privacy and identity protection. By choosing AVG's products, users become part of a trusted global community that engages directly with AVG to provide feedback and offer mutual support to other customers.
Barracuda Networks (NYSE:CUDA) provides cloud-connected security and storage solutions that simplify IT. These powerful, easy-to-use and affordable solutions are trusted by more than 150,000 organizations worldwide and are delivered in appliance, virtual appliance, cloud and hybrid deployments. Barracuda's customer-centric business model focuses on delivering high-value, subscription-based IT solutions that provide end-to-end network and data security.Barracuda Networks has developed a worldwide reputation as the go-to leader for providing government agencies with powerful yet easy-to-use IT solutions that simplify the most complex security, storage, application delivery, networking and data protection challenges.
BlackBerry (Research in motion) (NasdaqGS:BBRY; TSX:BB.TO) a global leader in wireless innovation, revolutionized the mobile industry with the introduction of the BlackBerry® solution in 1999. Today, BlackBerry products and services are used by millions of customers around the world to stay connected to the people and content that matter most throughout their day. Founded in 1984 and based in Waterloo, Ontario, RIM operates offices in North America, Europe, Asia Pacific and Latin America. Integral security features and an ever-expanding administrative toolset have earned BlackBerry® products the trust of some of the most secure organizations in the world. These security features have also made the BlackBerry solution a world leader in mobile security certifications
CA Technologies. (NasdaqGS:CA) provides IT management solutions that help customers manage and secure complex IT environments to support agile business services. Organizations leverage CA Technologies software and SaaS solutions to accelerate innovation, transform infrastructure and secure data and identities, from the data center to the cloud.
Cecurity.com (Paris:MLCEC.PA) is a French company and since 2001 the leader in publishing electronic vault software for the control of original digital documents. The areas of expertise of the Cecurity Group cover dematerialisation, legal archiving, data protection, traceability and certified electronic mail. Through its subsidiaries, the Cecurity Group is also a provider of services. These services are based on the use of its own technologies in SaaS (Software as a Service) mode.
Check Point Software Technologies Ltd. (NasdaqGS:CHKP) the worldwide leader in securing the Internet, provides customers with uncompromised protection against all types of threats, reduces security complexity and lowers total cost of ownership. Check Point first pioneered the industry with FireWall-1 and its patented stateful inspection technology. Today, Check Point continues to develop new innovations based on the Software Blade Architecture, providing customers with flexible and simple solutions that can be fully customized to meet the exact security needs of any organization. Check Point is the only vendor to go beyond technology and define security as a business process. Check Point 3D Security uniquely combines policy, people and enforcement for greater protection of information assets and helps organizations implement a blueprint for security that aligns with business needs. Customers include tens of thousands of organizations of all sizes, including all Fortune and Global 100 companies. Check Point's award-winning ZoneAlarm solutions protect millions of consumers from hackers, spyware and identity theft.
Cisco Systems Inc. (NASDAQGS: CSCO) is the worldwide leader in IT that helps companies seize the opportunities of tomorrow by proving that amazing things can happen when you connect the previously unconnected. Security Solutions
CommVault Systems, Inc. (NasdaqGS:CVLT) A singular vision – a belief in a better way to address current and future data management needs – guides CommVault in the development of Singular Information Management® solutions for high-performance data protection, universal availability and simplified management of data on complex storage networks. CommVault's exclusive single-platform architecture gives companies unprecedented control over data growth, costs and risk. CommVault's Simpana® software suite of products was designed to work together seamlessly from the ground up, sharing a single code and common function set, to deliver superlative Data Protection, Archive, Replication, Search and Resource Management capabilities. More companies every day join those who have discovered the unparalleled efficiency, performance, reliability, and control only CommVault can offer.
Computer Services, Inc. (CSI) (OTC: CSVI) delivers core processing, managed services, mobile and Internet solutions, payments processing, print and electronic distribution, and regulatory compliance solutions to financial institutions and corporate customers across the nation. Exceptional service, dynamic solutions and superior results are the foundation of CSI’s reputation and have resulted in the company’s inclusion in such top industry-wide rankings as the FinTech 100, Talkin’ Cloud 100 and MSPmentor Top 501 Global Managed Service Providers List. CSI Managed Security.
CSP Inc (NasdaqGM: CSPI) and its subsidiaries develop and market IT integration solutions and high-performance computer systems to meet the diverse requirements of our industrial, commercial, and defense customers worldwide. CSP, Inc's High Performance Products & Solutions segment includes the MultiComputer Division, which designs and manufactures commercial high-performance computer signal processing systems for a variety of complex real time applications in defense and commercial markets. The Company also owns Myricom, a pioneer in high performance computing interconnect technology. Founded in 1970, Modcomp, Inc. is part of CSPI's Information Technology Solutions segment, and has offices in North America and Europe. Modcomp provides solutions and services for complex IT environments including disaster recovery, mobility, managed services, security, data center management, and collaboration.
Cybergy Partners, Inc. (OTC:MKHD) team of approximately 110 employees delivers innovative technical and management services through its 3 divisions: New West Technologies, which was founded in 1996 and provides clean, smart, and reliable energy solutions and is a 5 time winner of the Inc. 500/5000 fastest growing private companies in America; Primetrix, which serves U.S. Federal Government contractor firms with contract procurement, compliance, and growth services; and Cybergy Labs, an award-winning developer of specialized cybersecurity software applications including SmartFile.
Digimarc Corp. (NasdaqGS:DMRC) is a leading innovator and provider of enabling technologies that create digital identities for all forms of media and many everyday objects. Digimarc's digital IDs are imperceptible to humans and enable computers, networks and devices like mobile phones to better "see, hear and understand" brand impressions and other objects of interest. Digimarc has built an extensive intellectual property portfolio with patents in digital watermarking, content identification and management, media and object discovery to enable ubiquitous computing and related technologies. Digimarc develops solutions, licenses its intellectual property, and provides development services to business partners across a range of industries.

See the full directory plus others: http://www.investorideas.com/membership/



About InvestorIdeas.com:
InvestorIdeas.com is a global news source for investors following leading business sectors including biotech, tech, mining, mobile, energy, water, defense and security, renewable energy, food and beverage stocks and Latin American stocks.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas

Sign up for our free news alerts

Become an Investorideas.com Member and use our online stock directories to research stocks – including cybersecurity, biometric and mobile payment stocks http://www.investorideas.com/membership/

Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp

BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.
800-665-0411 - Source – www.Investorideas.com





Wednesday, November 26, 2014

Biodefense Breaking News: Aethlon Medical (OTCBB: AEMD) Announces First Hemopurifier® Shipment To Support the Treatment of Ebola in the United States

Biodefense Breaking News: Aethlon Medical (OTCBB: AEMD) Announces First Hemopurifier® Shipment To Support the Treatment of Ebola in the United States

SAN DIEGO - November 26, 2014 (Investorideas.com newswire) Aethlon Medical, Inc. (OTCBB:AEMD), the pioneer in developing targeted therapeutic devices to address infectious disease and cancer, today announced the first shipment of Hemopurifier® therapy as a candidate to treat future Ebola virus infections in the United States. The Aethlon Hemopurifier® is a first-in-class bio-filtration device that targets the rapid elimination of viruses and immunosuppressive proteins from the circulatory system of infected individuals.


Aethlon disclosed that four Hemopurifiers have been shipped to the Biocontainment Unit at the Nebraska Medical Center (NMC) in Omaha as a therapeutic option to be stockpiled for Ebola patients that may be treated at the NMC. Aethlon further disclosed that it has provided onsite training to NMC clinical personnel related to the implementation of Hemopurifier® therapy within the dialysis infrastructure already located at the center.

The Nebraska Biocontainment Unit was commissioned by The United States Centers for Disease Control (CDC) in 2005. It is a joint project involving Nebraska Medicine, Nebraska Health and Human Services, and the University of Nebraska Medical Center. It was designed to provide the first line of treatment for people affected by bioterrorism or extremely infectious naturally occurring diseases such as Ebola. It's the largest facility of its kind in the U.S. The NMC has treated three Ebola patients since the current outbreak. Additional details can be found online at: www.nebraskamed.com/biocontainment-unit

Aethlon previously reported the successful administration of Hemopurifier® therapy to a Ugandan doctor who was infected with Ebola virus and treated at the Frankfurt University Hospital in Germany. At the time Hemopurifier® therapy was administered, the doctor was unconscious and suffered from multiple organ failure. His viral load prior to the administration of a single 6.5-hour Hemopurifier® treatment was measured at 400,000 virus copies per milliliter of blood (copies/ml). Post-treatment viral load was measured at 1,000 copies/ml and never again rose above that level. Viral load became undetectable five days after therapy. The treatment was well tolerated with no adverse events reported.

Additionally, a post-treatment elution protocol verified that 242 million Ebola viruses were captured within the Hemopurifier® during treatment. The doctor has since made a full recovery and has returned home to his family in Uganda.

In the United States, Hemopurifier® therapy is available to treat Ebola patients through FDA expanded access "emergency use" provisions to address life threatening circumstances for which an alternative therapy is not available. At present, no antiviral therapy or vaccine has proven to be effective against Ebola virus infection in humans. Aethlon disclosed that it provided Hemopurifiers to the NMC on a humanitarian basis and therefore will not generate revenues as a result of its initial shipment.

Aethlon will soon begin the first U.S. clinical Hemopurifier® studies following the United States Food and Drug Administration's (FDA)'s approval of an Investigational Device Exemption (IDE). The study will contribute safety data to advance the device as a broad-spectrum countermeasure against bioterror and pandemic threats, including Ebola and chronic viral pathogens such as HIV and Hepatitis C (HCV).


About Aethlon Medical, Inc.
Aethlon Medical creates targeted therapeutic devices to address infectious disease, cancer and neurodegenerative disorders. The company's lead product is the Aethlon Hemopurifier®, a first-in-class antiviral and immunotherapeutic device that selectively targets the broad-spectrum elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression. Exosome Sciences, Inc. is a majority owned subsidiary that is advancing exosome-based products to diagnose and monitor cancer, infectious disease and neurological disorders. For more information, please visit http://www.aethlonmedical.com and connect with the Company on Twitter, LinkedIn, Facebook and Google+.

Certain statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, that the ESI will not be able to commercialize its future products, that the FDA will not approve the initiation of the Company's clinical programs or provide market clearance of the company's products, future human studies whether revenue or non-revenue generating of the Aethlon ADAPT™ system or the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer or hepatitis C therapies or as a standalone cancer or hepatitis C therapy or as a broad spectrum defense against viral pathogens, including ebola, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, the ability of the Company to meet the milestones contemplated in the DARPA contract, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Contacts:
Leah-Michelle Nebbia (for interview requests) 
Golin
 
202-585-2651
 
lnebbia@golin.com

James A. Joyce 
Chairman and CEO
 
858.459.7800 x301
 
jj@aethlonmedical.com

Jim Frakes 
Chief Financial Officer
 
858.459.7800 x300
 
jfrakes@aethlonmedical.com

Visit this company: www.aethlonmedical.com

More info on AEMD at Investorideas.com Visit: http://www.investorideas.com/CO/AEMD/

Sign up for the free investor news and stock alerts:

Disclaimer/Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp Disclosure: AEMD subscribes to the Investorideas newswire content publishing annual program (9700 per Year, paid quarterly) for news publishing.
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

Become an Investorideas.com Member and access our 14 online stock directories 24/7 –biotech, defense, mining stocks, oil and gas stocks and more...






Tuesday, November 25, 2014

Ebola Patient Who Received Aethlon (OTCBB: AEMD) Hemopurifier® Therapy Has Been Discharged From Hospital

Biodefense Breaking News: Ebola Patient Who Received Aethlon (OTCBB: AEMD) Hemopurifier® Therapy Has Been Discharged From Hospital

SAN DIEGO - November 25, 2014 (Investorideas.com newswire) Aethlon Medical, Inc. (OTCBB:AEMD), the pioneer in developing targeted therapeutic devices to address infectious disease and cancer, disclosed today that an Ebola patient who received Hemopurifier® therapy has been reported to have been discharged from Frankfurt University Hospital in Germany. The patient was a Ugandan physician, who became infected with Ebola in Sierra Leone where he was treating other Ebola patients.



The Aethlon Hemopurifier® is a first-in-class bio-filtration device that targets the rapid elimination of viruses and immunosuppressive proteins from the circulatory system of infected individuals. At the time Hemopurifier® therapy was administered to the Ugandan physician, he was unconscious and suffered from multiple organ failure. His viral load prior to the administration of a single 6.5-hour Hemopurifier® treatment was measured at 400,000 virus copies per milliliter of blood (copies/ml). Post-treatment viral load was measured at 1,000 copies/ml and never again rose above that level. Viral load became undetectable five days after therapy. The treatment was well tolerated with no adverse events reported. Additionally, a post-treatment elution protocol verified that 242 million Ebola viruses were captured within the Hemopurifier® during treatment.

In the United States, Hemopurifier® therapy is available to treat Ebola patients through FDA expanded access "emergency use" provisions to address life threatening circumstances for which an alternative therapy is not available. At present, no antiviral therapy or vaccine has proven to be effective against Ebola virus infection in humans.

Aethlon will soon begin the first U.S. clinical Hemopurifier® studies following the United States Food and Drug Administration's (FDA)'s approval of an Investigational Device Exemption (IDE). The study will contribute safety data to advance the device as a broad-spectrum countermeasure against bioterror and pandemic threats, including Ebola and chronic viral pathogens such as HIV and Hepatitis C (HCV).


About Aethlon Medical, Inc.
Aethlon Medical creates targeted therapeutic devices to address infectious disease, cancer and neurodegenerative disorders. The company's lead product is the Aethlon Hemopurifier®, a first-in-class antiviral and immunotherapeutic device that selectively targets the broad-spectrum elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression. Exosome Sciences, Inc. is a majority owned subsidiary that is advancing exosome-based products to diagnose and monitor cancer, infectious disease and neurological disorders. For more information, please visit http://www.aethlonmedical.com and connect with the Company on Twitter, LinkedIn, Facebook and Google+.

Certain statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, that the ESI will not be able to commercialize its future products, that the FDA will not approve the initiation of the Company's clinical programs or provide market clearance of the company's products, future human studies whether revenue or non-revenue generating of the Aethlon ADAPT™ system or the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer or hepatitis C therapies or as a standalone cancer or hepatitis C therapy or as a broad spectrum defense against viral pathogens, including ebola, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, the ability of the Company to meet the milestones contemplated in the DARPA contract, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Contacts:
Leah-Michelle Nebbia (for interview requests) 
Golin
 
202-585-2651
 
lnebbia@golin.com

James A. Joyce 
Chairman and CEO
 
858.459.7800 x301
 
jj@aethlonmedical.com

Jim Frakes 
Chief Financial Officer
 
858.459.7800 x300
 
jfrakes@aethlonmedical.com

Visit this company: www.aethlonmedical.com

More info on AEMD at Investorideas.com Visit: http://www.investorideas.com/CO/AEMD/

Sign up for the free investor news and stock alerts:

Disclaimer/Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp Disclosure: AEMD subscribes to the Investorideas newswire content publishing annual program (9700 per Year, paid quarterly) for news publishing.
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

Become an Investorideas.com Member and access our 14 online stock directories 24/7 –biotech, defense, mining stocks, oil and gas stocks and more...





Friday, November 14, 2014

Biodefense News: Aethlon Medical's (OTCBB: AEMD) Hemopurifier® Used in Successful Treatment of Patient with Advanced Ebola Infection

Biodefense Breaking News: Aethlon Medical's (OTCBB: AEMD) Hemopurifier® Used in Successful Treatment of Patient with Advanced Ebola Infection

242 Million Copies of Ebola Virus Removed from Patient during Treatment, Physician Reports at American Society of Nephrology Annual Meeting

SAN DIEGO and PHILADELPHIA - November 14, 2014 (Investorideas.com newswire) The Aethlon Hemopurifier® was used in the successful treatment of a critically-ill Ebola-infected patient in Frankfurt, Germany, according to data presented today at the American Society of Nephrology (ASN) Annual Meeting by Helmut Geiger, M.D., Chief of Nephrology at Goethe University, Frankfurt University Hospital. Geiger reported that 242 million Ebola viruses were captured within the Aethlon Hemopurifier® during treatment, a number verified by a post-treatment elution protocol. The patient is no longer infected with Ebola virus and is expected to make a full recovery.


Aethlon Medical, Inc. (OTCBB:AEMD), the pioneer in developing targeted therapeutic devices to treat infectious disease, created the Hemopurifier®, a first-in-class bio-filtration device that targets the rapid elimination of viruses and immunosuppressive proteins from the circulatory system of infected individuals.

The Frankfurt University Hospital patient, a Ugandan physician, who was infected with Ebola in Sierra Leone where he was treating Ebola patients, was not administered Hemopurifier® therapy until 12 days after being diagnosed.

At the time of Hemopurifier® administration, Dr. Geiger reported that the Ebola patient was unconscious and suffering from multiple organ failure, which required mechanical ventilation, continuous dialysis and the administration of vasopressor medications.

The patient's viral load prior to the administration of a single 6.5-hour Hemopurifier® treatment was measured 400,000 virus copies per milliliter of blood (copies/ml). Post-treatment viral load was measured at 1,000 copies/ml and never again rose above that level. The treatment was well tolerated with no adverse events reported.

Since the administration of Hemopurifier® therapy, Frankfurt University Hospital officials have reported that Ebola virus is no longer detectable in the patient's blood and full recovery is expected.

"The rate of viral load reduction and magnitude of Ebola virus captured within the Hemopurifier® is quite remarkable when considering the lethality of Ebola infection and the compromised health of the patient," stated James A. Joyce, Chairman and CEO of Aethlon Medical. "We're thrilled for the patient and applaud the tireless effort of physicians in Frankfurt who helped to save the patient's life. We will continue to advance Hemopurifier® therapy as a lead candidate to address antiviral drug resistance and the sole broad-spectrum strategy to address Ebola other viruses where drugs and vaccines have not proven to be effective."

Aethlon will soon begin the first U.S. clinical Hemopurifier® studies following the United States Food and Drug Administration's (FDA)'s approval of an Investigational Device Exemption (IDE). The study will contribute safety data to advance the device as a broad-spectrum countermeasure against pandemic threats, including Ebola and chronic viral pathogens such as HIV and Hepatitis C (HCV).


About Aethlon Medical, Inc.
Aethlon Medical creates targeted therapeutic devices to address infectious disease, cancer and neurodegenerative disorders. The company's lead product is the Aethlon Hemopurifier®, a first-in-class antiviral and immunotherapeutic device that selectively targets the broad-spectrum elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression. Exosome Sciences, Inc. is a majority owned subsidiary that is advancing exosome-based products to diagnose and monitor cancer, infectious disease and neurological disorders. For more information, please visit http://www.aethlonmedical.com and connect with the Company on Twitter, LinkedIn,  Facebook and Google+.

Contacts:
Leah-Michelle Nebbia (for interview requests) 
Golin
 
202-585-2651
 
lnebbia@golin.com

James A. Joyce 
Chairman and CEO
 
858.459.7800 x301
 
jj@aethlonmedical.com

Jim Frakes 
Chief Financial Officer
 
858.459.7800 x300
 
jfrakes@aethlonmedical.com

Visit this company: www.aethlonmedical.com

More info on AEMD at Investorideas.com Visit: http://www.investorideas.com/CO/AEMD/

Sign up for the free investor news and stock alerts:

Disclaimer/Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp Disclosure: AEMD subscribes to the Investorideas newswire content publishing annual program (9700 per Year, paid quarterly) for news publishing.
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

Become an Investorideas.com Member and access our 14 online stock directories 24/7 –biotech, defense, mining stocks, oil and gas stocks and more...





Thursday, October 16, 2014

Experts and Analyst Comment on Recent Security Breaches for National Cybersecurity Month

Experts and Analyst Comment on Recent Security Breaches for National Cybersecurity Month

Scott Sacknoff of the SPADE Defense Index, Cybersecurity experts, Kiersten Todt & Roger Cressey, Gino Pereira, CEO of NXT-ID  and Scott L. Greiper, of Secure Strategy Group Share Insight

New York NY- Point Roberts WA - October 16, 2014 - Investorideas.com (www.investorideas.com), a global news source covering leading sectors including cybersecurity and biometrics, issues commentary from industry experts and analysts on recent security breaches (including Home Depot and JP Morgan) as National Cybersecurity Month drives even more awareness to the issue.

October 2014 marks the 11th Annual National Cyber Security Awareness Month, sponsored by the Department of Homeland Security, in cooperation with the National Cyber Security Alliance and the Multi-State Information Sharing and Analysis Center.

Scott Sacknoff of the SPADE Defense Index (NYSE: ^DXS) said looking at stocks in the sector, “With increasing publicity related to network attacks, an increasing number of companies are increasing their cybersecurity investments to be proactive rather than responsive to attacks. The proof of this trend can be seen as cybersecurity companies report gains in the size of their customer base as well as growth in the contracts awarded by the large, S&P100-type firms. One can expect firms such as Palo Alto Networks (PANW), FireEye (FEYE), Cyber-Ark Software (CYBR), Barracuda Networks (CUDA), and Fortinet (FTNT) to be among those that should benefit.”

Scott L. Greiper, President of Secure Strategy Group, LLC. told us, "The growing list of big-name hacking victims will support the broad secular growth being enjoyed by many companies in the cyber security sector.  Our SSG Small Cap Homeland Security Report for the first half of 2014 documents the strong performance of small caps in this sector. We anticipate growth will continue as the cyber threat and related legal concerns are taken seriously by more and more enterprises, especially small and medium companies.  To be sure, market participants need to step carefully given the presence of some inflated valuations and shifting technology requirements that can have rapid and significant impacts on certain providers.”

Cybersecurity experts, Kiersten Todt & Roger Cressey, Liberty Group Ventures commented, “National Cybersecurity Month has been dominated by news reports of successful attacks in cyberspace.  Millions of accounts, addresses, names, phone numbers, and other valuable data have been stolen.  Recent high profile cyber breaches into Home Depot and JP Morgan, in particular, have demonstrated the diverse and pervasive threats that businesses face.  What are some of the key lessons from these significant breaches? 

Corporate board members are now being held responsible and accountable for breaches.  Corporate leaders must view Cyber risk as a risk equal to credit, liquidity, and operational risks.  Assessing risk is an enterprise-wide endeavor, not merely a department, division, or company activity. The complexity of cybersecurity interdependencies is a growing challenge for companies to understand and manage.  Recent corporate breaches also reflect an increased diversification of threat actors who have significant capabilities and have exposed the difficulty in discerning whether a cybersecurity adversary is a nation-state or a sophisticated criminal organization. Companies should assume they are targets of a complete range of adversaries and intentions.

Employee behavior is a primary corporate vulnerability – spearphishing remains the primary way adversaries can infiltrate a network. Educating employees is the foundation of effective corporate cybersecurity and is often neglected.  Private organizations should not expect the government to identify threats first; information sharing between the public and private sectors is essential to maintaining security and companies must commit to continually improving methods for information sharing.

Every company can learn from past breaches and apply the best practices and lessons learned upon which industry and government have agreed.  One tool that companies have already begun to use effectively to manage cyber risk, enterprise-wide, is the application of the NIST Cybersecurity Framework.  In light of the recent court ruling requiring companies to take “reasonable efforts” on cybersecurity, application of the NIST Framework can be viewed as doing so.

No company can stop every cyber threat to its organization; companies will continue to be breached and the adversaries will continue to be more creative and opportunistic in finding vulnerabilities to exploit.  Tools and technologies that help organizations more effectively manage cyber risk will become essential for companies to prosper in the current threat environment.“

Gino Pereira, CEO of NXT-ID (NASDAQ: NXTD) said, “Companies need to approach cyber security from a holistic standpoint. Personnel, hardware and software all play a role. Authentication is a major factor. Passwords have been proven to be ineffective and biometrics are increasingly being used as a means of authentication of personnel.  Authentication should also rely on at least two factors to allow access.  Behavior of staff with access to sensitive information needs to be monitored.  Do they have outside internet access?  Can their behavior invite breaching attacks?  Companies should also look at keeping sensitive information in an encrypted format.  Here at NXT-ID, we are developing technologies that not only require dual authentication for access control but also dynamic pairing codes that change for each enquiry, making it very difficult for attackers to gain access to sensitive information.”

National Cyber Security Awareness Month is designed to engage and educate public and private sector partners through events and initiatives with the goal of raising awareness about cybersecurity and increasing the resiliency of the nation in the event of a cyber incident.


Investorideas.com has created a global cybersecurity stock directory for investors to research the sector. http://www.investorideas.com/Companies/HomelandDefense/Stock_List.asp#CyberSecurity


About InvestorIdeas.com:
InvestorIdeas.com is a global news source for investors following leading business sectors including cybersecurity.

Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas

Sign up for our free news alerts

Become an Investorideas.com Member and use our online stock directories to research stocks – including cyber, biometric and mobile payment stocks http://www.investorideas.com/membership/

Disclaimer/Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. Disclosure: Investorideas is compensated by NXTD five thousand per month plus 144 shares for PR, media and news publication.  .More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp

BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.
800-665-0411 - Source – www.Investorideas.com






Investorideas.com newswire